Diagnostik und Therapie des hepatorenalen Syndroms

Zusammenfassung

In Folge einer fortgeschrittenen Leberzirrhose kommt es zu einer portalen Hypertension, die für den überwiegenden Teil letaler Komplikationen bei Leberzirrhose verantwortlich ist. Die kompensatorische, splanchnische Vasodilatation führt langfristig zu einer Gegenregulation unter anderem über das Renin-Angiotensin-Aldosteron-System und dadurch zu einer Erhöhung des renalen Gefäßwiderstands. Hierdurch kann ein hepatorenales Syndrom (HRS) entstehen. Das HRS stellt sich als Nierenfunktionseinschränkung mit erhöhten Kreatinin-Werten dar. Das HRS wird über eine komplexe Ausschlussdiagnostik erkannt und rasch mittels Albumin und Vasokonstriktoren therapiert. Für eine Heilung ist die Verbesserung der Leberfunktion essenziell, was in vielen Fällen die Notwendigkeit einer Lebertransplantation bedeutet. Zur Überbrückung bis zur Transplantation kann die Anlage eines TIPS sinnvoll sein, sofern keine hepatische Enzephalopathie vorliegt. Da eine spontane bakterielle Peritonitis (SBP) ein erhebliches Risiko für die HRS-Entstehung ist, ist bei Patienten mit Leberzirrhose und SBP neben der Antibiotikagabe eine Prävention mittels Albumin ratsam.

Abstract

Portal hypertension occurs frequently in advanced liver cirrhosis and accounts for the majority of lethal complications. Compensatory splanchnic vasodilation and counter regulatory mechanisms (e. g. activation of the renin-angiotensin-aldosterone system) increase renal vascular resistance, which may facilitate acute kidney injury and the development of hepatorenal syndrome (HRS). HRS represents a functional, yet reversible renal impairment with elevated serum creatinine levels. Establishing the diagnosis, fluid challenge test and several investigations are needed to exclude acute kidney injury and other causes of renal failure. Early treatment with albumin and vasoconstrictors improves the prognosis of HRS patients. The only curative treatment of HRS so far is improvement of liver function implying liver transplantation in many cases. TIPS placement may be useful as a bridging tool to transplantation unless hepatic encephalopathy is present. Spontaneous bacterial peritonitis (SBP) is a relevant, independent risk factor for HRS. In patients with liver cirrhosis and SBP in addition to antibiotics, preventive albumin treatment is recommended.

Schlüsselwörter

Nierenversagen - Leberzirrhose - akutes Leberversagen - Intensivmedizin

Keywords

kidney failure - liver cirrhosis - acute liver failure - intensive care

^* Autoren des Hauptteils

^# Autoren des konkreten Falls

• Literatur

• 1 Gerbes AL, Sauerbruch T, Dathe K. Method report: German S3-guideline „ascites, spontaneous bacterial peritonitis, hepatorenal syndrome“. Z Gastroenterol 2011; 49: 780-787
• 2 Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066-1079
• 3 Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007; 41: S288-294
• 4 Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent Advances in Cirrhotic Cardiomyopathy. Dig Dis Sci 2015; 60: 1141-1151
• 5 Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447
• 6 Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010; 85: 451-458
• 7 Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236
• 8 Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
• 9 Martín-Llahí M, Guevara M, Torre A et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-496
• 10 Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
• 11 Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290
• 12 Salerno F, Gerbes A, Ginès P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
• 13 Salerno F, Cazzaniga M, Merli M et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011; 55: 1241-1248
• 14 Verna EC, Brown RS, Farrand E et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370
• 15 Belcher JM, Sanyal AJ, Peixoto AJ et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60: 622-632
• 16 Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
• 17 Piano S, Rosi S, Maresio G et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482-489
• 18 Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E / A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009; 104: 2458-2466
• 19 Saner FH, Neumann T, Canbay A et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 24: 425-432
• 20 Saner F, Kavuk I, Lang H et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 2004; 9: 78-82
• 21 Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014; 61: 396-407
• 22 Jürgens G, Müller M, Garidel P et al. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res 2002; 8: 115-126
• 23 Zarychanski R, Abou-Setta AM, Turgeon AF et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309: 678-688
• 24 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25: 880-885
• 25 Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179; author reply 1179-1181
• 26 Ghosh S, Choudhary NS, Sharma AK et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013; 33: 1187-1193
• 27 Hinz M, Wree A, Jochum C et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol 2013; 12: 92-99
• 28 Nazar A, Pereira GH, Guevara M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-226
• 29 Dechêne A, El Fouly AH, Bechmann LP et al. Acute management of refractory variceal bleeding in liver cirrhosis by self-expanding metal stents. Digestion 2012; 85: 185-191
• 30 Barreto R, Fagundes C, Guevara M et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology 2014; 59: 1505-1513
• 31 Bai M, Qi XS, Yang ZP et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20: 2704-2714
• 32 Yang Z, Han G, Wu Q et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1718-1725
• 33 Bañares R, Nevens F, Larsen FS et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology 2013; 57: 1153-1162
• 34 Kribben A, Gerken G, Haag S et al. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. Gastroenterology 2012; 142: 782-789 e3
• 35 Singh V, Dhungana SP, Singh B et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354
• 36 Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697
• 37 Esrailian E, Pantangco ER, Kyulo NL et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-748
• 38 Robertson M, Majumdar A, Garrett K et al. Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. Hepatology 2014; 60: 2125-2126
• 39 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11: 123-130 e1
• 40 Fernández J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824
• 41 Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; CD007339
• 42 García-Compean D, Blanc P, Larrey D et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002; 1: 29-35